THYROCARE2026-10-302026-10-30THYROCARE2026-10-30THYROCARE2026-10-302026-10-30PartiesOfTheAgreementDomain1THYROCARE2026-10-30PartiesOfTheAgreementDomain1THYROCARE2026-10-302026-10-30PartiesOfTheAgreementDomain2THYROCARE2026-10-30PartiesOfTheAgreementDomain2THYROCARE2026-10-302026-10-30PartiesOfTheAgreementDomain3THYROCARE2026-10-30PartiesOfTheAgreementDomain3THYROCARE2026-10-302026-10-30PartiesOfTheAgreementDomain4THYROCARE2026-10-30PartiesOfTheAgreementDomain4xbrli:purexbrli:sharesTHYROCAREThyrocare Technologies LimitedNewShareholder agreementsExecution of agreementListed Entityfalse2026-10-3017:08:00true2026-10-30Sale of the entire shareholding held by Thyrocare Technologies Limited (“the Company”) in Nueclear Healthcare Limited (“NHL”), a material wholly owned subsidiary of the Company, comprising 1,11,11,000 (One Crore Eleven Lakh Eleven Thousand) equity shares, representing 100% of the issued, subscribed and paid-up equity share capital of NHL, to Trovera Healthcare Private Limited. Accordingly, the Company has entered into a Share Purchase Agreement dated October 30, 2026, among the Company, NHL, Trovera Healthcare Private Limited and Dr. Prince Surana, for sale of the entire shareholding held by the Company in NHL, to Trovera Healthcare Private Limited (“Trovera” or “Purchaser”). The consideration will comprise (i) 42,500 (Forty Two Thousand Five Hundred) Compulsorily Convertible Preference Shares (“CCPS”) of Trovera, having a face value of Rs. 10/- each and issued at a premium of Rs. 13,990/- per CCPS, aggregating to Rs. 59,50,00,000/- (Rupees Fifty-Nine Crore Fifty Lakh only); and (ii) cash consideration of approximately Rs. 81,90,00,000/- (Rupees Eighty One Crore Ninety Lakh only), subject to adjustment upon determination of the working capital adjustment amount in accordance with the provisions of the SPA. The consideration will be received upon completion of the transaction in accordance with the terms of the SPA.2026-09-21falseThe Transaction is related to sale of wholly owned subsidiaryNo such impact of agreement on management and control of the listed entity4Thyrocare Technologies LimitedParty entering into the agreement000falseNueclear Healthcare LimitedParty entering into the agreement1111110001trueNueclear Healthcare Limited (“NHL”), a material wholly owned subsidiary of the CompanyTrovera Healthcare Private LimitedParty entering into the agreement000falseDr. Prince SuranaParty entering into the agreement000falsefalse2026-10-30Sale of the entire shareholding held by Thyrocare Technologies Limited (“the Company”) in Nueclear Healthcare Limited (“NHL”), a material wholly owned subsidiary of the Company, comprising 1,11,11,000 (One Crore Eleven Lakh Eleven Thousand) equity shares, representing 100% of the issued, subscribed and paid-up equity share capital of NHL, to Trovera Healthcare Private Limited. The consideration will comprise (i) 42,500 (Forty Two Thousand Five Hundred) Compulsorily Convertible Preference Shares (“CCPS”) of Trovera, having a face value of Rs. 10/- each and issued at a premium of Rs. 13,990/- per CCPS, aggregating to Rs. 59,50,00,000/- (Rupees Fifty-Nine Crore Fifty Lakh only); and (ii) cash consideration of approximately Rs. 81,90,00,000/- (Rupees Eighty One Crore Ninety Lakh only), subject to adjustment upon determination of the working capital adjustment amount in accordance with the provisions of the SPA. The consideration will be received upon completion of the transaction in accordance with the terms of the SPA.Key terms of the SPA: (a) The completion under the SPA is subject to customary conditions precedent. (b) Pursuant to transfer of shares of NHL by the Company, as contemplated under the SPA, NHL will become wholly owned subsidiary of the Purchaser. (c) The purchase consideration will be discharged by way of cash consideration and issuance of securities of the Purchaser, as per the SPA.falseNo restriction or liability imposed upon the listed entityNil. No such control is exercised by any of the parties over the Company, and neither of the parties has the right to nominate or appoint any director on the Board of Directors of the Company. Accordingly, no potential conflict of interest arises in this regardNo shares are being issued by the Company to any of the parties. However, as part of the total consideration set out in the SPA, the Company will subscribe to 42,500 Compulsorily Convertible Preference Shares (CCPS) of Trovera, having a face value of Rs. 10/- each, issued at a premium of Rs. 13,990/- per CCPS.